1. AddLife Year-end report February, 2017

2. AddLife introduction
A leading independent player mainly in the Nordic Life Science market
Markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector in the Nordics
30 subsidiaries
Labtech and Medtech
Net sales ~SEK 1 950m

3. Other markets/operations
AddLife Markets
Other markets/operations
Production plant
Key markets

4. Customer offering – built on 4 cornerstones
Products from leading suppliers
Qualified advisory services
Strong local service and support
Training services

5. ”Radiometer award – 75 years of partnership!”

6. Two business areas Labtech Products Customers Companies Medtech

7. Decentralized organization with entrepreneurial business acumen
Combine the small company’s…
With the large company’s…
Flexibility
Resources
”Small scale business – large scale wise”
Personality
Network
Effectiveness
Sustainability

8. Year-end &Q3 2016

9. Highlights Q3 ”Record quarter concludes the year”
Net Sales SEK 612m (472), +30%, organic, +21%
EBITA SEK 76m (42), +80%
Year-end, 9 months
Net Sales SEK 1.486m (1,110), +34%, organic, +13%
EBITA SEK 154m(100), +54%
Proposes a dividend of SEK 1.50 per share for the shortened financial year

10. Market update Q3 & Year-end 2016
The market continues to develop positively and so do our companies. Our organic growth outperforms the market both in the Q3 and 2016!
Positive development in all Nordic countries from the healthcare sector, especially within diagnostics, both instruments and consumables. High competition for large public tenders.
Increased investments within start-up companies and innovation clusters.
Acqusitions of Svan Care and Biolin Scientific in Q3, adding SEK 135m in annual sales
Integration of Medline in Q3, adding SEK 40m in annual sales
Acquired companies and integrated businesses during 2016, adding totally ~ SEK 275m in annual sales, developed well and according to plan
Events after the period:
Acquisition of Techno Medica, ~ SEK 30m in annual sales

11. Market update Q3 & Year-end 2016
Both public and private grants to different research-projects within Life Science.
Somewhat lower investments in public research. Pharma industry continues to be strong. Digital marketing efforts yielding results.
Somewhat weaker demands in university research, but increased sales of consumables.
Continued stable market. Increased number of tenders from primary care.
Continued increase growth outside the Nordics

12. Labtech Comments Organic sales growth of 26% in Q and 16% YTD
Acquired sales growth of 6% in Q and 2% YTD
Biolin Scientific acquired in Q3
The market continue to develop positively, especially for the diagnostics
Both high instrument sales and high sales of consumables
Severe influenza season
Focused digital marketing and webshop in Denmark
EBITA increase during Q3 by 65%, corresponding to an EBITA-margin of 15.6% (12.5)
EBITA increase during YTD by 39%, corresponding to an EBITA-margin of 12.8% (10.9)
YoY +33%

13. Medtech Comments Organic sales growth of 12% in Q and 7% YTD
Acquired sales growth of 12% in Q and 62% YTD
Svan Care acquired and Medline integrated in Q3
Demand from health services continues to develop favorably
Growth is strongest in Sweden, Finland and Benelux
Challenging market with strong competition
Improved product mix to own products within ear, nose and throat together with infusion and surgery
EBITA increased during Q3 by 63% corresponding to an EBITA- margin of 9.0% (6.9)
EBITA increased during YTD by 120% corresponding to an EBITA-margin of 8.0% (6.2)
YoY +24%

14. Profitability (P/WC) Cash Flow
Cash flow from operating activities amounted to SEK 96m (62)
Increased operating cash due to higher profit
For the nine month period, other financing activities are the net of rights issue of SEK 300m, payment of bank loan of SEK 250m and repurchase of own shares SEK 33m
Return on working capital (P/WC) amounted to 62% (64)
Change in P/WC is attributable to the increase EBITA

15. Balance sheet Rights issue of SEK 300m in Q1
Repurchase of own shares SEK 33.1m

16. Selected key financial ratios

17. Q & A